You are here

L2 Diagnostics, LLC

Company Information
Address
300 George St Ste 309
New Haven, CT 06511-6662
United States



Information

DUNS: 142406110

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

    Amount: $298,911.00

    The advent of checkpoint inhibitor (CPI) therapy in human cancer has dramatically changed the landscape of treatment strategies in recent years. Previously, cancers with largely ineffective therapeuti ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  2. An antigen-detection assay to diagnose Babesia microti infection

    Amount: $692,082.00

    PROJECT SUMMARY Human babesiosis is a malaria-like multisystem disease caused primarily by Babesia microti, an emerging apicomplexan parasite that infects and develops within human erythrocytes. The p ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  3. Vaccination against Zika virus infection using mosquito NeSt1 protein

    Amount: $299,200.00

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main trans ...

    STTRPhase I2020Department of Health and Human Services National Institutes of Health
  4. A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1

    Amount: $594,226.00

    PROJECT SUMMARYZika virus, an emerging flavivirus, is associated with severe clinical outcomes, including Guillain-Barré syndrome and birth defects. Transmission of Zika virus is primarily mosquito- ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  5. Development of A Narrow Spectrum Anti-Tubercular Agent

    Amount: $585,337.00

    Abstract Complex and lengthy treatment regimens coupled with rising drug resistance underscore the urgent need for new and better drugs to treat tuberculosis (TB) caused by the bacterium Mycobacterium ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  6. Targets of Acquired Tick-Resistance As Anti-Tick Vaccines

    Amount: $596,625.00

    ABSTRACTThis proposal seeks to develop a novel vaccine against pathogens transmitted by the blacklegged tick, Ixodes scapularis, by targeting tick salivary proteins (Salps) critical for tick feeding. ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  7. Immunization with mosquito AgTRIO protein to prevent malaria

    Amount: $592,338.00

    PROJECT SUMMARYMalaria is one of the world’s major public health threats. The disease is transmitted when an infected female Anopheles mosquito, while probing for a blood meal, injects saliva togeth ...

    STTRPhase I2019Department of Health and Human Services National Institutes of Health
  8. An antigen-detection assay to diagnose Babesia microti infection

    Amount: $299,975.00

    Project Summary Human babesiosis is a malaria like multisystem disease caused primarily by Babesia microtian emerging apicomplexan parasite that infects and develops within human erythrocytesThe paras ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  9. Therapeutic Inhibition of MIF to Improve Glucocorticoid Response

    Amount: $453,442.00

    Abstract Despite the advent of biological therapiesglucocorticoidsGCsremain the most widely prescribed medicines for the management of inflammatory diseases such as lupusasthmamultiple sclerosisand rh ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  10. Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus

    Amount: $225,000.00

    ABSTRACT Systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are characterized by polyclonal T cell activation driving the production of pathogenic class switche ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government